ClinicalTrials.gg
CompletedNCT04578600Updated Apr 24, 2025

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

A Phase 1 interventional study of Lenalidomide and Obinutuzumab in Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma and Recurrent Chronic Lymphocytic Leukemia, sponsored by Joseph Tuscano. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Primary conditionLymphoma, B-Cell, Marginal ZoneRegistry: Lymphoma, B-CellReclassifiedWhy we changed it
Registry
Lymphoma, B-Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, B-Cell, Marginal Zone
Why
  1. The study's listed conditions name Lymphoma, B-Cell, Marginal Zone, a narrower term within Lymphoma, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Joseph Tuscano · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone — 5 open to participants now, 7 under way, 1 of them phase 3. Lenalidomide · Lymphoma, B-Cell, Marginal Zone.

Enrollment
25th of 29
8 · median 36
Started
2020
with 2 others
Phase 1
10 of 30
none open now
Registered
23rd of 30
by date

Among the 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone, this one is the 25th largest by enrollment of the 29 interventional ones that give a count, is one of 3 that started in 2020, is one of 10 in phase 1, and was the 23rd registered.

Lymphoma, B-Cell, Marginal Zone

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Open to participants now

5 of the 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 93 Lymphoma, B-Cell, Marginal Zone studies recruiting now, 78 (84%) set no upper age limit and 7 (8%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing lenalidomide in Lymphoma, B-Cell, Marginal Zone, or all of them as a file.
02

Study summary

This phase I/Ib trial investigates the side effects of CC-486 and how well it works in combination with lenalidomide and obinutuzumab in treating patients with CD20 positive B-cell lymphoma that has come back (recurrent) or has not responded to treatment (refractory). Chemotherapy drugs, such as CC-486, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide is a drug that alters the immune system and may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may reduce or prevent the growth of cancer cells. Obinutuzumab is a type of antibody therapy that targets and attaches to the CD20 proteins found on follicular lymphoma cells as well as some healthy blood cells. Once attached to the CD20 protein the obinutuzumab is thought to work in different ways, including by helping the immune system destroy the cancer cells and by destroying the cancer cells directly. Giving CC-486 with lenalidomide and obinutuzumab may improve response rates, quality, and duration, and minimize adverse events in patients with B-cell lymphoma.

Read the detailed description

PRIMARY OBJECTIVE:

To assess the safety and toxicity of oral azacitidine (CC-486) in combination with lenalidomide and obinutuzumab.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of CC-486 in combination with lenalidomide and obinutuzumab in subjects with relapsed/refractory indolent B-cell lymphoma as assessed by:

Ia. Overall response rate: complete response (CR) + partial response (PR) per 2016 Lugano criteria and Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) criteria.

Ib. Duration of response (DOR): will be calculated from time of initial response assessment demonstrating at least PR until disease response assessment that demonstrates progressive disease.

Ic. Time to response (TTR): calculated as time from registration to first disease response assessment that demonstrates at least PR.

Id. Progression-free survival (PFS): Patients are considered a failure for this endpoint if they die or if they relapse/progress or receive additional anti-lymphoma therapy.

Ie. Determine the recommended phase 2 dose (RP2D).

03

Conditions studied

  • Indolent B-Cell Non-Hodgkin Lymphoma
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • Recurrent Chronic Lymphocytic Leukemia
  • Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
  • Recurrent Follicular Lymphoma
  • Recurrent Hairy Cell Leukemia
  • Recurrent Lymphoplasmacytic Lymphoma
  • Recurrent Mantle Cell Lymphoma
  • Recurrent Marginal Zone Lymphoma
  • Refractory B-Cell Non-Hodgkin Lymphoma
  • Refractory Chronic Lymphocytic Leukemia
  • Refractory Mucosa-Associated Lymphoid Tissue Lymphoma
  • Refractory Follicular Lymphoma
  • Refractory Hairy Cell Leukemia
  • Refractory Lymphoplasmacytic Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Refractory Marginal Zone Lymphoma
  • Recurrent Small Lymphocytic Lymphoma
  • Refractory Small Lymphocytic Lymphoma
04

In context

Lymphoma, B-Cell, Marginal Zone Reclassified

877 studies on the registry are indexed under Lymphoma, B-Cell, Marginal Zone; 113 are open to participants now.

This study's enrollment of 8 is below the median of 40 across 683 interventional studies indexed under Lymphoma, B-Cell, Marginal Zone.

Browse Lymphoma, B-Cell, Marginal Zone studies →

Lead sponsor

Joseph Tuscano is the lead sponsor of 5 studies on the registry; none are open to participants now.

Compared within Lymphoma, B-Cell, Marginal Zone, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, B-Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated, confirmed CD20+ B cell lymphoma which includes mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, hairy cell leukemia, marginal zone lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, and lymphoplasmacytic lymphoma. Fine needle aspirates are not acceptable
  • Ability to understand and willingness to sign an form
  • Ability to adhere to the study visit schedule and other protocol requirements
  • (ECOG) performance status score of 0 or 1, or performance status (KPS) performance status of 60% or greater
  • >= 3 months
  • Leukocytes >= 3,000/uL
  • >= 1,000/uL
  • >= 50,000/uL
  • Total : =\< 2.0 x institutional (ULN)
  • (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =\< 2.5 x institutional ULN
  • Serum creatinine

    • =\< 2.0 x ULN, OR
    • Calculated >= 30 ml/min/1.73 M\^2 by the modified Cockcroft and Gault Formula, OR
    • Creatinine clearance >= 30 mL/min obtained from a 24-hour urine collection
  • At least one according to International workshop lymphoma response criteria. There must be measurable lymphadenopathy to follow with serial exam and/or imaging
  • All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study
  • Submission of original for review and verification by participating center hematopathologist
  • Disease free of prior for >= 3 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast
  • All study participants must be registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategies (REMS) program, and be willing and able to comply with the requirements of the REMS program
  • Females of must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program
  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. (Subjects intolerant to acetylsalicylic acid [ASA] may use low molecular weight heparin)
  • Must be able to swallow study drugs
  • (HIV) infected patients are eligible provided they meet all the other eligibility criteria of the study in addition to the following:

    • No history of acquired immunodeficiency syndrome (AIDS)-defining conditions other than lymphoma or history of CD4+ T-cells below 200/mm\^3 prior to beginning combination antiretroviral therapy (cART)
    • After HIV diagnosis and during treatment with cART, patients should have maintained CD4+ T-cells >= 350/mm\^3 prior to lymphoma diagnosis. Patents who never immune reconstituted to a stable level above 350/mm\^3 are not eligible
    • At time of study entry CD4+ T-cells must have recovered from prior lymphoma therapy to >= 250/mm\^3
    • At the time of study entry the HIV viral load must be undetectable by standard laboratory assay
    • During prior lymphoma therapy, patients must not have experienced documented infections attributed to the HIV+ status
    • No history of non-adherence to cART and willing to adhere to cART while on study
    • Antiretroviral drugs with overlapping or similar toxicity profiles as study agents not allowed:

      • Efavirenz not allowed due to potential central nervous system (CNS) toxicity
      • Stavudine not allowed due to potential neuropathic effects
      • Zidovudine not allowed due to myelosuppressive effects
    • Patients must be willing to be followed at a minimum of approximately every 3 months by physician expert in HIV disease management

Exclusion criteria

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
  • Use of any other experimental drug or therapy within 28 days of baseline
  • Known to lenalidomide, thalidomide, obinutuzumab, or mannitol
  • A history of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs
  • Any prior use of obinutuzumab or CC-486
  • Concurrent use of other anti-cancer agents or treatments
  • Known active or C. Patients on suppressive therapy with a negative viral load and no evidence of hepatic damage are eligible
  • Uncontrolled systemic fungal, bacterial or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy and/or other treatment)
  • Active central nervous system (CNS) involvement by lymphoma, including
  • Active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. A history of hemolytic anemia associated with the lymphoma does not exclude a patient from the study
  • Pregnant or breast feeding females. (Lactating females must agree not to breast feed while taking azacitidine)
  • For CC-486: History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease (i.e., sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the study drug (CC-486) and/or predispose the subject to an increased risk of gastrointestinal toxicity
  • Abnormal coagulation parameters ( [PT] > 15 seconds, partial thromboplastin time [PTT] > 40 seconds, and/or international normalized ratio [INR] > 1.5)
  • Significant active cardiac disease within the previous 6 months including:

    • (NYHA) class 4 congestive heart failure (CHF)
    • Unstable angina
    • Myocardial infarction
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment (lenalidomide, oral azacitidine, obinutuzumab)

    Patients receive azacitidine PO QD on days 1-21, obinutuzumab IV over on days 8, 15, 22, and 29, and lenalidomide PO QD on days 8-28 of cycle 1. Treatment continues for 35 days in the absence of disease progression or unacceptable toxicity. Patients then receive azacitidine PO QD on days 1-21, obinutuzumab IV over on day 1, and lenalidomide PO QD on days 1-21. Cycles repeats every 28 days in the absence of disease progression, unacceptable toxicity, or until stem cell transplant. Patients who achieve SD, PR, or CR do not proceed to stem cell transplant may continue treatment for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

    Drug: Lenalidomide · Biological: Obinutuzumab · Drug: Oral Azacitidine

Interventions

  • Given PO

    Also known as: CC-5013, CC5013, CDC 501, Revlimid

  • BiologicalObinutuzumab

    Given IV

    Also known as: Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759

  • DrugCc-486Studies of Cc-486Cc-486 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: CC-486

07

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Safety summaries will include tabulations in the form of tables and listings. The frequency (number and percentage) of treatment-emergent AEs will be reported. The frequency of treatment-emergent AEs requiring discontinuation of study drug or dose reductions will be reported. Additional AE summaries will include AE frequency by AE severity and by relationship to study drug. Toxicity data by type and severity will be summarized by frequency tables. Per-treated analysis will be performed to include any patient who received the treatment regardless of the eligibility nor the duration or dose of the treatment received.

    Time frame: Up to 30 days post-last dose

Secondary outcomes

  1. Complete response rate

    Response will be assessed based on Cheson, Lugano classification 2016. The number and percentage of subjects with a complete response at 120 weeks will be tabulated.

    Time frame: At 48 weeks

  2. Overall response rate (ORR) (complete response + partial response)

    Will be assessed by the investigator based on Cheson, Lugano classification 2016. The number and percentage of subjects with an ORR will be tabulated. The best ORR will be recorded.

    Time frame: Up to 2 years

  3. Duration of response

    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.

    Time frame: From the time by which measurement criteria for complete response or partial response, whichever is recorded first, is met until death or the first date by which progressive disease is documented, assessed up to 2 years

  4. Time to response

    Comparison by important subgroups will be made using the log-rank test. Will be estimated using the product-limit method of Kaplan and Meier.

    Time frame: From registration to first disease response assessment that demonstrates at least partial response, assessed up to 2 years

  5. Progression-free survival

    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.

    Time frame: From the date of first dose (cycle 1, day 1) to the date of first documented progression or death, assessed up to 2 years.

  6. Recommended phase 2 dose

    The maximum tolerated dose (MTD) will be defined as the highest dose of CC-486 tested in which fewer than 33% of patients experience a dose-limiting toxicity and at least 6 patients have been treated at that dose. The MTD will be the recommended phase 2 dose, provided that other safety considerations are acceptable.

    Time frame: Up to 35 days

  7. Time to next treatment

    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.

    Time frame: From the end of cycle 24 (each cycle is 28 days) to the date of first documented new anti-lymphoma treatment, assessed up to 2 years.

  8. Event-free survival

    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.

    Time frame: From the date of first dose (cycle 1, day 1) to the date of first documented progression, transformation to diffuse large B-cell lymphoma, initiation of new anti-lymphoma treatment, or death, assessed up to 2 years.

  9. Overall survival

    Kaplan-Meier methodology will be used to estimate event-free curves, median, and 95% confidence interval. Comparison by important subgroups will be made using the log-rank test.

    Time frame: From the date of first dose (cycle 1, day 1) to the date of death regardless of cause, assessed up to years.

08

Study locations

1 site
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Dec 2023, 37 months.

Of 46 non-industry phase 1 interventional studies under Lymphoma, B-Cell, Marginal Zone, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 108. This study's 37 months is below that.

Counting every sponsor, half of 81 studies reached it within 57 months; a quarter within 38 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2020
First posted
Oct 8, 2020
StartActual
Oct 23, 2020
Primary completionActual
Dec 12, 2023
CompletionActual
Feb 21, 2025
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04578600
Lead sponsor
Joseph Tuscano
Responsible party
Joseph Tuscano (Principal Investigator, University of California, Davis) — Sponsor-investigator
First posted
Oct 8, 2020
Start date
Oct 23, 2020
Primary completion
Dec 12, 2023
Completion
Feb 21, 2025
Last update
Apr 24, 2025

Study contacts

Joseph M Tuscano
principal investigator · University of California, Davis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Obinutuzumab · Cc-486

Start the discussion